When using antibodies СD 47 for therapy of solid tumors, we are faced with the emergence of fatal hemolytic anemia in all control mice.
Two methods we applied in order to avoid symptoms of anemia-a decrease in the rate of injection of the antibody or compound molecules CD 47 with the virus. But both negatively modify the properties of the antibodies against the tumor processes.
Please share experience and knowledge on how to avoid hemolytic anemia when using antibodies CD-47
Dear colleague. To protect red blood cells when using antibodies CD47 not possible, because this glycoprotein is the major RBC receptor and ligand.
If you know how this is possible - I am ready to join forces in search of opportunities.
The solution to this problem (in my opinion) is very important in the possibility of applying an effective anticancer therapy.
Thanks for the links
"Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof"
see: https://www.google.com/patents/US20140140989
- Badges
- Science topic
- Similar topics
- Biological Science
- Immunology
- Antibodies